TrialInternational journal of clinical oncology2018

Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study.

Shuichi Mizuta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.